Chiral Phosphoric Acid-Catalyzed Synthesis of Fluorinated 5,6-Dihydroindolo[1,2-c]quinazolines with Quaternary Stereocenters


Xin-Wei Wang,^{†,‡,§}[®] Mu-Wang Chen,[†][®] Bo Wu,[†] Baomin Wang,[§][®] and Yong-Gui Zhou^{*,†,‡}[®]

[†]State Key Laboratory of Catalysis, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, P. R. China [‡]University of Chinese Academy of Sciences, Beijing 100049, P. R. China

[§]State Key Laboratory of Fine Chemicals, Dalian University of Technology, Dalian 116024, P. R. China

S Supporting Information

ABSTRACT: A chiral phosphoric acid-catalyzed enantioselective synthesis of fluorinated 5,6-dihydroindolo[1,2-c]quinazolines has been developed by a condensation/amine addition cascade from 2-(1*H*-indolyl)anilines and fluorinated ketones, giving the fluorinated aminals with quaternary stereogenic centers with excellent yields and up to 97% ee. A series of the fluorinated aromatic, aliphatic ketones, and ethyl trifluoropyruvate are suitable.



C hiral aminal moieties are a common structural unit in myriad natural products, synthetic pharmaceutical molecules, and chiral catalysts.¹ Among them, the optically active 5,6-dihydroindolo[1,2-c]quinazolines could be also found in natural products and pharmaceutical molecules.² For instance, (-)-goniomitine is a natural occurring alkaloid,^{2a} and compound **A** is an original semisynthetic cytotoxic bisindole alkaloid^{2b} (Figure 1).




Figure 1. Selected bioactive 5,6-dihydroindolo[1,2-*c*]quinazolines.

Owing to the importance of chiral aminals, continuous efforts have been devoted to synthesis of these compounds. In 2003, Ramsden's group reported the first enantioselective synthesis of the chiral aminal by asymmetric hydrogenation of a dihydropyrrolobenzothiadiazine dioxide using a diphosphine ruthenium diamine catalyst with 87% ee.³ Since then, some efficient methods have been successfully developed for synthesis of chiral aminals. Enantioselective amidations of imines catalyzed by VAPOL-derived phosphoric acid were developed by Antilla's group.⁴ Asymmetric cyclization of aldehydes or aldimines with 2-aminobenzamides, 2-aminobenzenesulfona-mides, and N-(2,6-diisopropylbenzyl)ethane-1,2-diamineand 2-(1H-pyrrol-2-yl)aniline could be catalyzed by Brønsted acids,⁵ Lewis acids,⁶ and organocatalysts, respectively. Diastereo- and enantioselective [3 + 2], [3 + 2]and $\begin{bmatrix} 4 + 2 \end{bmatrix}^{10}$ cycloadditions were also established. 3], Antilla's, You's, and Ma's groups demonstrated asymmetric

cascade dearomatization procedures for the formation of pyrroloindolines.¹¹ Chiral phosphoric acid-catalyzed asymmetric tandem 1,5-hydride transfer/ring closing to give cyclic aminals was disclosed by Gong's group.¹² Li and co-workers described a novel approach to aminals via palladium-catalyzed C–N coupling with chiral bisphosphine monooxides.¹³ Enantioselective N–H functionalizations of indoles catalyzed by chiral phosphoric acids or dinuclear zinc-ProPhenol were realized.¹⁴

Compared to chiral aminals containing tertiary stereocenters, asymmetric synthesis of chiral aminals bearing quaternary stereocenters have been relatively less studied owing to low activity of ketones and ketimines. Consequently, the reactions of highly reactive cyclic isatins were investigated by List, ^{5a} Shi, ^{9,15} and Wang¹⁶ to give spirocyclic aminals using chiral phosphoric acids as catalysts. Another approach to chiral aminals containing quaternary stereocenters is enantioselective hydrazination of α -aminocarbonyl compounds by organocatalysis.¹⁷ Recently, Zhong and co-workers demonstrated a chiral SPINOL-derived phosphoric acid-catalyzed asymmetric *N*-alkylation reaction of indoles and 3-aryl 3-hydroxyisoindolinones with excellent enantioselectivities.^{14d}

The chemistry of organofluorine compounds has been of great importance, since the incorporation of fluorine into organic molecules can modify their physical, chemical, and biological properties.¹⁸ However, asymmetric synthesis of fluorinated aminals has been rarely explored. Wang's group developed Cu(I)-catalyzed 1,3-dipolar cycloaddition of azomethine ylides with fluorinated imines for synthesis of fluorinated imidazolidines (Scheme 1a).^{8b} Toste and co-workers demonstrated enantioselective synthesis of fluoro-dihydroquinazolones by fluorination-initiated asymmetric cyclization (Scheme 1b).¹⁹ Cation-directed highly enantiose-

Received:
 April 10, 2019

 Published:
 May 27, 2019


Scheme 1. Synthesis of Chiral Fluorinated Aminals

Cu(I)-catalyzed Asymmetric 1,3-Dipolar Cycloaddition by Wang (2013)


$$PMP_{N} \swarrow_{R_{f}} + R^{N} \wedge_{CO_{2}Me} \xrightarrow{Cu(1)/L} \xrightarrow{PMP_{N}}_{R \leftarrow M} \overset{R_{f}}{\overset{V'' CO_{2}Me}}$$
(a)

Fluorination-initiated Asymmetric Cyclization Reactions by Toste (2016)

Asymmetric Phase-transfer Catalysis by Smith Group (2016)




This work: Brønsted Acid-Catalyzed Synthesis of Chiral Aminals



lective *N*-functionalization of pyrroles was developed by the Smith group, which was the only enantioselective synthesis of chiral aminals with quaternary stereogenic centers from linear aliphatic ketones (Scheme 1c).^{7a} The method acquired prepreparation of ketimines by condensation of 2-(1*H*-pyrrol-2-yl)aniline and excess trifluoromethyl ketones with moderate yields. Due to relatively lower reactivity of linear aromatic ketones for enantioselective synthesis of aminals has not been documented. Herein, we reported a chiral phosphoric acid-catalyzed direct enantioselective synthesis of fluorinated 5,6-dihydroindolo[1,2-*c*]quinazolines with quaternary stereocenters from linear fluorinated ketones and 2-(1*H*-indolyl)anilines with excellent yields and up to 97% ee (Scheme 1d).

Initially, we chose 5 mol % of chiral phosphoric acid (R)-4a as the catalyst to test the reaction of 2-(1H-indolyl)aniline 1a and simple trifluoromethyl phenyl ketone 2a in toluene at room temperature, but no reaction was observed. To our delight, the desired product 3aa could be obtained in 61% yield and 92% ee when the reaction was performed at 80 °C for 48 h (Table 1, entry 1). Subsequently, different solvents, including 1,2-dichloroethane, acetonitrile, and 1,4-dioxane, were examined (Table 1, entries 2-4). The results revealed that solvent effect played a crucial role; toluene is the best in terms of yield and enantioselectivity. Further screening of aromatic solvents showed that toluene was more suitable than the others (Table 1, entries 5-7). Subsequently, some commercially available chiral phosphoric acids were evaluated using toluene as the solvent (Table 1, entries 8-14). It should be noted, that steric hindrance of the substituted groups at the 3,3'-positions of chiral phosphoric acids displayed a profound influence on enantioselectivity and reactivity. The sterically congested catalysts furnished the reaction in higher yields (Table 1, entries 10-13 vs 8-9). However, catalyst (R)-4h, bearing a triphenylsilyl group at the 3,3'-positions of the binaphthyl unit, was not effective (Table 1, entry 14). In the presence of 50 mg of 5 Å MS as the dehydrating agent, the reaction proceeded smoothly, giving 3aa in 71% yield without

Table 1. Optimization of the Reaction Conditions^a




-	()				
3	(R)- 4a	MeCN	80	13	89 (R)
4	(R)- 4a	1,4-dioxane	80	<5	
5	(R)- 4a	benzene	80	35	93 (R)
6	(R)- 4a	o-xylene	80	50	92 (R)
7	(R)- 4a	PhCl	80	79	87 (R)
8	(S)- 4b	toluene	80	36	15 (S)
9	(S)- 4c	toluene	80	31	10 (S)
10	(S)- 4d	toluene	80	70	50 (S)
11	(R)- 4e	toluene	80	59	40 (R)
12	(S)- 4f	toluene	80	92	75 (S)
13	(S)- 4g	toluene	80	91	73 (S)
14	(R)- 4h	toluene	80	<5	
15 ^d	(R)- 4a	toluene	80	71	92 (R)
16 ^e	(R)- 4a	toluene	80	95	90 (R)
17 ^e	(R)- 4a	toluene	70	81	94 (R)
18 ^e	(R)- 4a	toluene	90	97	85 (R)
19 ^{e,f}	(R)- 4a	toluene	70	97	90 (R)
20 ^{<i>e</i>,g}	(R)- 4a	toluene	70	45	94 (R)
21 ^{<i>e</i>,<i>j</i>}	(R)- 4a	toluene	70	94	92 (R)

^{*a*}Conditions: **1a** (0.10 mmol) and **2a** (0.10 mmol) in toluene (1.0 mL) using 5 mol % **4** as catalyst at 80 °C for 48 h. ^{*b*}Determined by ¹H NMR. ^{*c*}Determined by HPLC. ^{*d*}50 mg of 5 Å MS was used. ^{*e*}50 mg of 5 Å MS and **2a** (0.15 mmol) were used. ^{*f*}0.5 mL of toluene was used. ^{*g*}2.0 mL of toluene was used. ^{*j*}72 h.

influence of enantisoselectivity (Table 1, entry 15). Increasing the ratio of 2a to 1.5 equiv, the yield can be improved to 95% with a slightly lower ee (Table 1, entry 16). When the reaction temperature was decreased to 70 °C, 94% ee could be obtained (Table 1, entry 17) albeit with low reactivity. Raising the temperature to 90 °C, the ee value dropped to 85% (Table 1, entry 18). Additionally, the reaction concentrations had remarkable influences on reactivity (Table 1, entries 19 and 20). The reaction time was prolonged to 72 h using 1.0 mL of toluene, and a 94% yield and 92% ee could be gained (Table 1, entry 21). Finally, the optimized reaction condition was established using 5 mol % (R)-4a as the catalyst and 1.5 equiv of 2a to 1a in the presence of 50 mg of 5 Å MS in toluene (0.1 M) for 72 h.

Under the optimal condition, a series of substrates were explored to determine the generality of this method, and the results are summarized in Scheme 2. Most of substrates performed well under the standard reaction conditions. Aromatic trifluoromethyl ketones bearing electron-withdrawing groups and weak electron-donating groups delivered the corresponding products in high yields with excellent enantioselectivities (Scheme 2, 3aa–3ad and 3af–3ag). The 4-methoxyl-substituted ketone 2e afforded expected 3ae with a

Scheme 2. Substrate Scope^a



^{*a*}Conditions: **1** (0.20 mmol) and **2** (0.3 mmol) in toluene (2.0 mL) using 5 mol % (*R*)-4a as catalyst in the presence of 100 mg of 5 Å MS at 70 °C for 72 h. ^{*b*}70 °C for 120 h. ^{*c*}90 °C for 120 h. ^{*d*}70 °C for 12 h.

moderate 60% yield and 89% ee after a prolonged time. In addition, 2-naphthyl trifluoromethyl ketone 2h gave 95% ee. Next, the reaction of various 2-(1*H*-indolyl)anilines and ketone 2a was investigated (Scheme 2, 3ba-3ga). With no substituent at the 3-position of indole, the *N*-functionalization of 1b was predominant in 74% yield with 88% ee, and the C3-alkylation side-product was isolated (see the Experimental Section). 3-Ethylindole 1c underwent smoothly and gave 3ca in 90% yield and 92% ee (Scheme 2, 3ca). The substituted groups at the *meta*-position of the aniline moiety increased enantioselectivities (Scheme 2, 3da and 3ea). With an electron-withdrawing group, aniline 1d gave product 3da with 28% yield and 96% ee

(Scheme 2, 3da). When the reaction temperature was raised to 90 °C for 120 h, a limited influence of yield and stereoselectivity was observed. The best enantioselectivity was given with *m*-methyl-substituted anline 1e (Scheme 2, 3ea). The 5-bromo-substituted indole 1f gave a product with a relatively higher ee than the 5-methoxyl-substituted indole 1g (Scheme 2, 3fa vs 3ga). The pentafluoroethyl ketone 2i gave poor reactivity (Scheme 2, 3ai), and the reason is not clear. The difluoromethyl ketone 2j afforded 3aj in quantitative yield but with a poor 25% ee. Furthermore, alphatic trifluoromethyl ketone 2k furnished the reaction with good yield and enantioselectivity (Scheme 2, 3ak). The absolute configuration of product 3aa was assigned as *R* based on the X-ray diffraction analysis after recrystallization from mixed solvents of methanol/ethyl acetate/hexanes to upgrade ee to >99%.


Acetophenone was also tested under the above standard condition. To our surprise, the corresponding aminal could be isolated with 94% yield but poor enantioselectivity (Scheme 2, 3al). Changing the reaction conditions could not obviously improve the enantioselectivity. The experimental results show that the trifluoromethyl group plays a vital role in enantiocontrol. In recent years, the fluorine effect was observed in asymmetric organocatalysis by many groups.²⁰ For example, the Lin group observed a remarkable fluorine effect in chiral phosphoric acid-catalyzed asymmetric synthesis of bihydrobenzoxazinones, and mechanistic studies through combination theory calculations with the experimental suggested the CF₃ moiety serving as an attractive hydrogen-bond acceptor.^{20c} On the basis of the previous reports, we speculated the reactivity trends may also owe to the fluorine effect or possible H…F hydrogen bond between fluorine and N-H of indole or chiral phosphoric acid.

 α -Diamino acids and derivatives were valuable and unusual substructures with important biological and pharmacological properties, such as anticonvulsant activity.²¹ To the best of our knowledge, catalytic enantioselective synthesis of chiral α -diamino acids has not been reported. Then, we expanded the reaction of ethyl trifluoropyruvate **2m**. 2-(1*H*-Indolyl)aniline **1a** reacted with **2m** to afford the desired **3am** with 75% yield and 89% ee after lowering the temperature to 50 °C for 42 h (Scheme 3, **3am**). The other two anilines (**1e** and **1f**) were used, and moderate yields and 91 and 89% ee were observed (Scheme 3, **3em** and **3fm**).

The product transformation was conducted (Scheme 4). The α -diamino ester **3am** could be converted to the corresponding α -diaminoalcohol **5** with sodium borohydride in methanol without loss of optical purity.

In conclusion, we have developed a chiral phosphoric acidcatalyzed condensation/amine addition cascade for synthesis

Scheme 3. Substrate Scope: Ethyl Trifluoropyruvate



DOI: 10.1021/acs.joc.9b00985 J. Org. Chem. 2019, 84, 8300-8308

Scheme 4. Product Transformation



of chiral fluorinated aminals with quaternary stereocenters, giving the chiral dihydroindolo[1,2-c]quinazolines with good yields and up to 97% ee. The substrate scope could be extended to aromatic, aliphatic trifluoromethyl ketones and ethyl trifluoropyruvate. Detailed mechanistic studies and further expanding the scope of this chemistry are currently ongoing in our laboratory.

EXPERIMENTAL SECTION

Commercially, all reactions were carried out under an atmosphere of nitrogen using the standard Schlenk techniques, unless otherwise noted. Commercially available reagents were used without further purification. Solvents were treated prior to use according to the standard methods. ¹H NMR and ¹³C NMR spectra were recorded at 400 and 100 MHz with the Bruker spectrometer. ¹⁹F was recorded at 376 MHz with a Bruker spectrometer. Chemical shifts are reported in ppm using tetramethylsilane as an internal standard when using CDCl₃, CD₂Cl₂, and CD₃OD as a solvent for ¹H NMR spectra. The following abbreviations were used to symbolize the multiplicities, s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, and br = broad. Flash column chromatography was performed on silica gel (200-300 mesh). All reactions were monitored by TLC analysis. Optical rotations were measured by the polarimeter. Enantiomeric excess was determined by HPLC analysis using a chiral column described below in detail. High-resolution mass spectrometry (HRMS) was measured on an electrospray ionization (ESI) apparatus using time-of-flight (TOF) mass spectrometry.

Procedures for Synthesis of 2-(1*H***-Indolyl)anilines 1.** 2-(1*H*-Indolyl)aniline derivatives 1a and 1c–1g could be conveniently synthesized from the indoles and 2-nitrobromobenzenes in two steps according to the known literature procedures with minor modification.^{22,23} 1b was prepared by Fisher indole synthesis according to a reported method.²⁴ Among them, compound 1b is the known compound.²⁴

General Procedure A for Synthesis of 2-(1*H***-Indolyl)anilines 1a, 1c, 1e, and 1g.** 2-(2-Nitrophenyl)-1*H*-indoles were prepared from indoles and 1-bromo-2-nitrobenzenes in the presence of cesium carbonate under reflux with acetonitrile as solvent. The corresponding 2-(1*H*-indolyl)anilines could be obtained after reduction of the above nitro-compounds using Pd/C as a catalyst under hydrogen gas.

In a dried round bottomed flask, were added indoles (0.20 mol), 1bromo-2-nitrobenzenes (0.10 mol), cesium carbonate (0.20 mol, 65.16 g), and anhydrous acetonitrile (500 mL). The resulting suspension was stirred for 24 h under an inert atmosphere under reflux. The solvent was evaporated under vacuum, and water was added. The mixture was extracted with ethyl acetate ($3 \times 100 \text{ mL}$). The combined organic layers were washed with water and brine, dried with anhydrous sodium sulfate, and concentrated under reduced pressure. The crude product was purified by flash column chromatography to give the crude product.

The above crude product (28.1 mmol) was dissolved in ethanol (250 mL) and dichloromethane (5 mL), Pd/C (1.200 g, 10 wt %) was added, and the mixture was stirred under hydrogen gas (balloon pressure) overnight. The mixture was filtered through Celite, and the solvent was evaporated under the reduced pressure. The residue was purified by column chromatography on silica gel using hexanes and ethyl acetate as eluent to give the desired compound 1.

General Procedure B for Synthesis of 2-(1*H*-IndolyI)anilines 1d and 1f. 2-(2-NitrophenyI)-1*H*-indoles could be synthesized from indoles and 1-bromo-2-nitrobenzenes. Reduction of them by employing iron powder and concentrated hydrochloric acid gave 2-(1*H*-indolyl)anilines 1d and 1f.

In a dried round bottomed flask was added indoles (0.20 mol), 1bromo-2-nitrobenzenes (0.10 mol), cesium carbonate (0.20 mol, 65.16 g), and anhydrous acetonitrile (500 mL). The resulting suspension was stirred for 24 h under inert atmosphere under reflux. The solvent was evaporated under vacuum, and water was added. The mixture was extracted with ethyl acetate (3 × 100 mL). The combined organic layers were washed with water and brine, dried with anhydrous sodium sulfate, and concentrated under reduced pressure. The crude product was purified by flash column chromatography to give the crude product.

To a solution of 2-(2-nitrophenyl)-1*H*-indoles (5.62 mmol) in ethanol (24 mL), were added iron powder (33.72 mmol, 1.888 g) and concentrated hydrogen chloride (6.0 mL) under nitrogen. The mixture was stirred under reflux for 4 h. After being cooled to room temperature, excess sodium hydroxide solution was added. The mixture was extracted with ethyl acetate (3×50 mL). The combined organic layers were washed with water and brine and dried over anhydrous sodium sulfate. After being concentrated under the reduced pressure, the residue was purified by flash column chromatography to afford the pure product **1**.

2-(3-Methyl-1H-indol-2-yl)aniline (1a). 5.340 g, 24% yield in 2 steps. Yellow solid. mp 105–107 °C. New compound. $R_f = 0.35$ (hexanes/ethyl acetate 10:1). ¹H NMR (400 MHz, CDCl₃, δ): 7.99 (brs, 1H), 7.60 (d, J = 7.6 Hz, 1H), 7.31 (d, J = 7.8 Hz, 1H), 7.26–7.11 (m, 4H), 6.90–6.70 (m, 2H), 3.82 (brs, 2H), 2.28 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃, δ): 145.0, 136.0, 131.8, 131.2, 129.5, 129.4, 122.1, 119.4, 118.8, 118.39, 118.36, 115.7, 110.7, 109.8, 9.4. HRMS (ESI-TOF) (m/z): $[M + H]^+$ calculated for C₁₅H₁₅N₂, 223.1230; found, 223.1235.

2-(3-Ethyl-1H-indol-2-yl)aniline (1c). 0.831 g, 18% yield in 2 steps. Yellow oil. New compound. $R_f = 0.30$ (hexanes/ethyl acetate 10:1). ¹H NMR (400 MHz, CD₃OD, δ): 7.58 (d, J = 7.8 Hz, 1H), 7.35 (d, J = 8.0 Hz, 1H), 7.22–7.14 (m, 2H), 7.13–7.07 (m, 1H), 7.06–7.00 (m, 1H), 6.85 (d, J = 7.9 Hz, 1H), 6.81–6.74 (m, 1H), 2.72 (q, J = 7.5 Hz, 2H), 1.21 (t, J = 7.5 Hz, 3H). ¹³C{¹H} NMR (100 MHz, CD₃OD, δ): 145.8, 136.7, 131.7, 130.8, 128.8, 128.1, 120.9, 118.9, 118.19, 118.18, 117.3, 115.3, 114.8, 110.6, 17.5, 14.5. HRMS (ESITOF) (m/z): [M + H]⁺ calculated for C₁₆H₁₇N₂, 237.1386; found, 237.1390.

5-Bromo-2-(3-methyl-1H-indol-2-yl)aniline (1d). 1.072 g, 18% yield in 2 steps. Yellow solid. mp 163–164 °C. New compound. R_f = 0.30 (hexanes/ethyl acetate 10:1). ¹H NMR (400 MHz, CD₃OD, δ): 7.41 (d, *J* = 7.8 Hz, 1H), 7.23 (d, *J* = 8.0 Hz, 1H), 7.04–6.98 (m, 1H), 6.97–6.88 (m, 3H), 6.75 (dd, *J* = 8.1, 2.0 Hz, 1H), 2.12 (s, 3H). ¹³C{¹H} NMR (100 MHz, CD₃OD, δ): 147.5, 136.6, 132.1, 131.1, 129.1, 122.3, 121.2, 119.5, 118.4, 117.9, 117.3, 110.5, 108.2, 8.1. HRMS (ESI-TOF) (*m*/*z*): [M + H]⁺ calculated for C₁₅H₁₄BrN₂, 301.0335; found, 301.0331.

5-Methyl-2-(3-methyl-1H-indol-2-yl)aniline (1e). 1.034 g, 22% yield in 2 steps. Yellow oil. New compound. $R_f = 0.35$ (hexanes/ethyl acetate 10:1). ¹H NMR (400 MHz, CD₃OD, δ): 7.51 (d, J = 7.8 Hz, 1H), 7.33 (d, J = 8.0 Hz, 1H), 7.13–7.06 (m, 2H), 7.06–7.01 (m, 1H), 6.69 (s, 1H), 6.62 (d, J = 7.7 Hz, 1H), 2.30 (s, 3H), 2.22 (s, 3H). ¹³C{¹H} NMR (100 MHz, CD₃OD, δ): 145.3, 138.7, 136.5, 132.4, 130.6, 129.2, 120.9, 118.5, 118.2, 117.8, 116.2, 116.0, 110.4, 107.7, 20.1, 8.1. HRMS (ESI-TOF) (m/z): [M + H]⁺ calculated for C₁₆H₁₇N₂, 237.1386; found, 237.1402.

2-(5-Bromo-3-methyl-1H-indol-2-yl)aniline (1f). 1.059 g, 23% yield in 2 steps. Yellow oil. New compound. $R_f = 0.20$ (hexanes/ethyl acetate 10:1). ¹H NMR (400 MHz, CD₃OD, δ): 7.54 (d, J = 1.6 Hz, 1H), 7.18–7.03 (m, 1H), 7.11–7.04 (m, 3H), 6.79–6.73 (m, 1H), 6.70–6.64 (m, 1H), 2.09 (s, 3H). ¹³C{¹H} NMR (100 MHz, CD₃OD, δ): 145.7, 135.1, 134.0, 131.0, 130.6, 129.0, 123.5, 120.4, 118.0, 117.3, 115.4, 112.0, 111.4, 107.6, 7.9. HRMS (ESI-TOF) (m/z): [M + H]⁺ calculated for C₁₅H₁₄BrN₂, 301.0335; found, 301.0334.

Procedures for Enantioselective Synthesis of Chiral 5,6-Dihydroindolo[1,2-c]quinazolines. To a 25 mL sealed tube charged with 2-(1*H*-indolyl)anilines 1 (0.20 mmol), chiral phosphoric acid TRIP (R)-4a (7.5 mg, 0.01 mmol), dry toluene (2.0 mL), and 5 Å MS (100 mg) was added ketone 2 (0.3 mmol) under nitrogen. The mixture was kept stirring at 70 °C for 72 h. The solvent was evaporated under reduced pressure and the residue was purified by flash column chromatography on a silica gel using hexanes/ethyl acetate as the eluent to give the desirable products 3.

(*R*)-(+)-12-*Methy*I-6-*pheny*I-6-(*trifluoromethy*I)-5, 6*dihydroindolo*[1,2-*c*]*quinazoline* (**3***aa*). 71 mg, 94% yield. White solid. mp 96–97 °C. New compound. *R_f* = 0.65 (hexanes/ethyl acetate 10:1), 93% ee, $[\alpha]^{20}_{D}$ = +61.54 (*c* 1.42, EtOAc). ¹H NMR (400 MHz, CDCl₃, δ): 7.97 (d, *J* = 7.8 Hz, 1H), 7.77 (d, *J* = 7.6 Hz, 2H), 7.62 (d, *J* = 7.9 Hz, 1H), 7.58–7.43 (m, 3H), 7.20 (t, *J* = 7.2 Hz, 1H), 7.14–7.00 (m, 2H), 6.86 (t, *J* = 7.7 Hz, 1H), 6.77 (d, *J* = 7.8 Hz, 1H), 6.25 (d, *J* = 8.4 Hz, 1H), 4.67 (brs, 1H), 2.74 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃, δ): 138.1, 136.4, 134.7, 130.7, 130.1, 129.6, 128.9, 128.4, 127.8, 125.6 (q, *J* = 296.0 Hz), 125.1, 122.1, 120.3, 120.0, 118.4, 117.1, 113.7, 112.8, 108.5, 75.4 (q, *J* = 30 Hz), 11.1. ¹⁹F{¹H} NMR (376 MHz, CDCl₃, δ): -72.0. Enantiomeric excess was determined by HPLC (IA column; elute, *n*-hexane/*i*-PrOH = 98/ 2; detector, 254 nm; flow rate, 1.0 mL/min; 30 °C), retention time 7.2 min (major) and 9.5 min. HRMS (ESI-TOF) (*m*/*z*): [M + H]⁺ calculated for C₂₃H₁₈F₃N₂, 379.1417; found, 379.1421.

(+)-6-(4-Fluorophenyl)-12-methyl-6-(trifluoromethyl)-5,6dihydroindolo[1,2-c]quinazoline (3ab). 68 mg, 86% yield. Colorless oil. New compound. $R_f = 0.70$ (hexanes/ethyl acetate 10:1), 91% ee, $[\alpha]^{20}_{D} = +48.23 \text{ (c } 1.36, \text{ EtOAc}).$ ¹H NMR (400 MHz, CD₃OD, δ): 7.75 (d, J = 7.8 Hz, 1H), 7.66-7.52 (m, 2H), 7.42 (d, J = 7.9 Hz, 1H), 7.14–6.97 (m, 3H), 6.87 (t, J = 7.5 Hz, 1H), 6.80 (t, J = 7.5 Hz, 1H), 6.75 (d, J = 7.9 Hz, 1H), 6.66 (t, J = 7.5 Hz, 1H), 6.10 (d, J = 8.4 Hz, 1H) 2.52 (s, 3H). ¹³C{¹H} NMR (100 MHz, CD₃OD, δ): 163.2 (d, J = 247.0 Hz), 139.4, 134.5, 133.0 (d, J = 3.0 Hz), 130.7, 130.6(dq, J = 8.0 Hz, J = 1.0 Hz), 129.8, 127.6, 125.8 (q, J = 296.0 Hz),124.4, 121.4, 119.6, 118.9, 117.8, 116.2, 115.1 (d, J = 22.0 Hz), 113.3, 112.3, 107.2, 75.0 (q, J = 30.0 Hz), 9.7. ¹⁹F{¹H} NMR (376 MHz, CD_3OD , δ): -73.3 (s, 3F), -113.3 (s, 1F). Enantiomeric excess was determined by HPLC (IA column; elute. n-hexane/i-PrOH = 95/5; detector. 254 nm; flow rate. 1.0 mL/min; 30 °C), retention time 5.9 min (major) and 6.9 min. HRMS (ESI-TOF) (m/z): $[M + H]^+$ calculated for C₂₃H₁₇F₄N₂, 397.1322; found, 397.1350.

(+)-6-(4-Chlorophenyl)-12-methyl-6-(trifluoromethyl)-5,6dihydroindolo[1,2-c]quinazoline (3ac). 77 mg, 93% yield. Colorless oil. New compound. $R_f = 0.80$ (hexanes/ethyl acetate 10:1), 91% ee, $[\alpha]^{20}_{D} = +64.67 \text{ (c } 1.54 \text{, EtOAc}\text{)}$. ¹H NMR (400 MHz, CD₃OD, δ): 7.71 (dd, J = 7.9, 0.9 Hz, 1H), 7.48 (d, J = 8.1 Hz, 2H), 7.37 (d, J = 7.9 Hz, 1H), 7.27 (d, J = 8.8 Hz, 2H), 7.01–6.94 (m,, 1H), 6.87–6.80 (m, 1H), 6.80–6.69 (m, 2H), 6.67–6.59 (m, 1H), 6.09 (d, J = 8.4 Hz, 1H), 2.47 (s, 3H). ¹³C{¹H} NMR (100 MHz, CD₃OD, δ): 139.3, 135.6, 135.4, 134.4, 130.7, 129.9, 129.7, 128.4, 127.6, 125.7 (q, J = 295.0 Hz), 124.4 121.4, 119.7, 118.9, 117.9, 116.2, 113.3, 112.3, 107.3, 75.0 (q, J = 30.0 Hz), 9.7. ¹⁹F{¹H} NMR (376 MHz, CD₃OD, δ): -73.2. Enantiomeric excess was determined by HPLC (IA column; elute, *n*-hexane/*i*-PrOH = 95/5; detector, 254 nm; flow rate, 1.0 mL/min; 30 °C), retention time 6.0 min (major) and 7.4 min. HRMS (ESI-TOF) (m/z): $[M + H]^+$ calculated for $C_{23}H_{17}ClF_3N_{27}$ 413.1027; found, 413.1041.

(+)-6-(4-Bromophenyl)-12-methyl-6-(trifluoromethyl)-5,6dihydroindolo[1,2-c]quinazoline (**3ad**). 84 mg, 91% yield. Colorless oil. New compound. $R_f = 0.70$ (hexanes/ethyl acetate 10:1), 92% ee, $[\alpha]^{20}_{D} = +58.26$ (*c* 1.67, EtOAc). ¹H NMR (400 MHz, CD₃OD, δ): 7.75 (d, *J* = 7.7 Hz, 1H), 7.55–7.37 (m, 5H), 7.06–6.96 (m, 1H), 6.88 (t, *J* = 7.3 Hz, 1H), 6.80 (t, *J* = 7.6 Hz, 1H), 6.74 (d, *J* = 7.9 Hz, 1H), 6.71–6.62 (m, 1H), 6.12 (d, *J* = 8.4 Hz, 1H), 2.52 (s, 3H). ¹³C{¹H} NMR (100 MHz, CD₃OD, δ): 139.2, 136.1, 134.4, 131.5, 130.7, 130.1, 129.7, 127.6, 125.7 (q, *J* = 295.0 Hz), 124.4, 123.6, 121.5, 119.7, 119.0, 117.9, 116.2, 113.4, 112.3, 107.4, 75.1 (q, *J* = 30.0 Hz), 9.8. ¹⁹F{¹H} NMR (376 MHz, CD₃OD, δ): -73.3 (s, 3F). Enantiomeric excess was determined by HPLC (IA column; elute, *n*-hexane/*i*-PrOH = 95/5; detector, 254 nm; flow rate, 1.0 mL/min; 30 °C), retention time 6.5 min (major) and 7.9 min. HRMS (ESI-TOF) $(m/z) \colon [M + H]^+$ calculated for $C_{23}H_{17}BrF_3N_2$, 457.0522; found, 457.0517.

(+)-6-(4-Methoxyphenyl)-12-methyl-6-(trifluoromethyl)-5,6dihydroindolo[1,2-c]quinazoline (3ae). 49 mg, 60% yield. Colorless oil. New compound. $R_f = 0.25$ (hexanes/ethyl acetate 20:1), 89% ee, $[\alpha]_{D}^{20}$ = +45.30 (c 0.98, EtOAc). ¹H NMR (400 MHz, CD₃OD, δ): 7.74 (d, J = 7.9 Hz, 1H), 7.47 (d, J = 8.5 Hz, 2H), 7.40 (d, J = 8.0 Hz, 1H), 7.00 (t, J = 7.7 Hz, 1H), 6.89-6.81 (m, 3H), 6.81-6.75 (m, 1H), 6.72 (d, J = 8.0 Hz, 1H), 6.66–6.59 (m, 1H), 6.13 (d, J = 8.5Hz, 1H), 3.68 (s, 3H), 2.51 (s, 3H). ¹³C{¹H} NMR (100 MHz, CD₃OD, δ): 160.6, 139.6, 134.7, 130.6, 129.8, 129.6, 128.6, 127.5, 126.0 (q, J = 295.0 Hz), 124.3, 121.2, 119.4, 118.7, 117.6, 116.3, 113.5, 113.3, 112.6, 107.0, 75.1 (q, J = 30.0 Hz), 54.4, 9.7. ¹⁹F{¹H} NMR (376 MHz, CD₃OD, δ): -73.4. Enantiomeric excess was determined by HPLC (IA column; elute, *n*-hexane/*i*-PrOH = 95/5; detector, 254 nm; flow rate, 1.0 mL/min; 30 °C), retention time 8.6 min (major) and 10.7 min. HRMS (ESI-TOF) (m/z): $[M + H]^+$ calculated for C₂₄H₂₀F₃N₂O, 409.1522; found, 409.1533.

(+)-12-Methyl-6-(p-tolyl)-6-(trifluoromethyl)-5,6-dihydroindolo-[1,2-c]quinazoline (3af). 69 mg, 88% yield. Colorless oil. New compound. $R_{f} = 0.30$ (hexanes/ethyl acetate 50:1), 92% ee, $[\alpha]^{20}_{D} =$ +54.85 (c 1.38, EtOAc). ¹H NMR (400 MHz, CD₃OD, δ): 7.72 (d, J = 7.8, 1H), 6.47–6.33 (m, 3H), 7.10 (d, J = 8.1 Hz, 2H), 6.97 (t, J = 7.4 Hz, 1H), 6.83 (t, J = 7.5 Hz, 1H), 6.76 (t, J = 7.5 Hz, 1H), 6.70 (d, J = 7.9 Hz, 1H), 6.57 (t, J = 7.6 Hz, 1H) 6.09 (d, J = 8.4 Hz, 1H), 2.49 (s, 3H), 2.23 (s, 3H). ${}^{13}C{}^{1}H$ NMR (100 MHz, CD₃OD, δ): 139.7, 139.5, 134.6, 133.9, 130.6, 129.8, 128.8, 128.1, 127.5, 126.0 (q. *J* = 295.0 Hz), 124.3, 121.2, 119.4, 118.7, 117.6, 116.2, 113.3, 112.6, 107.0, 75.2 (q, J = 30.0 Hz), 19.8, 9.8. ¹⁹F{¹H} NMR (376 MHz, CD₂OD, δ): -73.2. Enantiomeric excess was determined by HPLC (IA column; elute, n-hexane/i-PrOH = 98/2; detector, 254 nm; flow rate, 1.0 mL/min; 30 °C), retention time 7.2 min (major) and 11.0 min. HRMS (ESI-TOF) (m/z): $[M + H]^+$ calculated for $C_{24}H_{20}F_3N_{21}$ 393.1573; found, 393.1608.

(+)-12-Methyl-6-(m-tolyl)-6-(trifluoromethyl)-5,6-dihydroindolo-[1,2-c]quinazoline (3ag). 67 mg, 85% yield. White solid. mp 150-151 °C. New compound. $R_f = 0.30$ (hexanes/ethyl acetate 50:1), 93% ee, $[\alpha]_{D}^{20}$ = +60.67 (c 1.34, EtOAc). ¹H NMR (400 MHz, CD₃OD, δ): 7.73 (d, J = 7.8, 1H), 7.44–7.31 (m, 3H), 7.23–7.11 (m, 2H), 6.97 (t, J = 7.5 Hz, 1H), 6.82 (t, J = 7.5 Hz, 1H), 6.75 (t, J = 7.6 Hz, 1H), 6.70 (d, J = 7.9 Hz, 1H), 6.58 (t, J = 7.7 Hz, 1H), 6.09 (d, J = 8.4 Hz, 1H), 2.49 (s, 3H), 2.15 (s, 3H). ¹³C{¹H} NMR (100 MHz, CH₃OD, δ): 139.5, 138.3, 136.8, 134.6, 130.6, 130.1, 129.8, 128.9, 128.0, 127.5, 126.0 (q, J = 295.0 Hz), 125.0, 124.4, 121.2, 119.5, 118.7, 117.7, 116.2, 113.3, 112.6, 107.0, 75.3 (q, J = 29.0 Hz), 20.2, 9.8. ${}^{19}F{}^{1}H$ NMR (376 MHz, CH₃OD, δ): -73.1. Enantiomeric excess was determined by HPLC (IA column; elute, n-hexane/i-PrOH = 95/5; detector, 254 nm; flow rate, 1.0 mL/min; 30 °C), retention time 4.8 min (major) and 6.2 min. HRMS (ESI-TOF) (m/z): [M + H]⁺ calculated for C₂₄H₂₀F₃N₂, 393.1573; found, 393.1608.

(+)-12-Methyl-6-(naphthalen-2-yl)-6-(trifluoromethyl)-5,6dihydroindolo[1,2-c]quinazoline (3ah). 68 mg, 79% yield. White solid. mp 214–215 °C. New compound. $R_f = 0.30$ (hexanes/ethyl acetate 100:1), 95% ee, $[\alpha]^{20}_{D}$ = +20.85 (*c* 1.18, EtOAc). ¹H NMR (400 MHz, CD₂Cl₂, δ): 8.28 (s, 1H), 7.94–7.85 (m, 2H), 7.84–7.73 (m, 2H), 7.59-7.41 (m, 4H), 7.13-7.05 (m, 1H), 6.70-6.88 (m, 2H), 6.72-6.57 (m, 2H), 6.18 (d, J = 8.5 Hz, 1H), 4.71 (brs, 1H), 2.63 (s, 3H). ¹³C{¹H} NMR (100 MHz, CD₂Cl₂, δ): 138.1, 134.7, 133.6, 133.4, 132.4, 130.7, 129.5, 129.1, 129.0, 127.9, 127.8, 127.6, 127.0, 126.9 (q, J = 3.0 Hz), 125.77, 125.76 (q, J = 295.0 Hz), 125.0, 122.1, 120.2, 120.1, 118.4, 116.8, 113.8, 112.6, 108.6, 75.6 (q, J = 30.0 Hz), 10.8. ${}^{19}F{}^{1}H{}$ NMR (376 MHz, CD_2Cl_2 , δ): -72.1. Enantiomeric excess was determined by HPLC (IA column; elute. *n*-hexane/*i*-PrOH = 95/5; detector, 254 nm; flow rate, 1.0 mL/min; 30 °C), retention time 7.3 min (major) and 10.5 min. HRMS (ESI-TOF) (m/z): $[M + H]^+$ calculated for $C_{27}H_{20}F_3N_2$, 429.1573; found, 429.1571.

(+)-6-Phenyl-6-(trifluoromethyl)-5,6-dihydroindolo[1,2-c]quinazoline (**3ba**). 54 mg, 74% yield. Colorless oil. New compound. $R_f = 0.60$ (hexanes/ethyl acetate 20:1), 88% ee, $[\alpha]^{20}_{D} = +97.40$ (c 1.08, EtOAc). ¹H NMR (400 MHz, CD₃OD, δ): 7.61 (d, *J* = 7.7 Hz, 3H), 7.44–7.28 (m, 4H), 7.05–6.96 (m, 1H), 6.90–6.79 (m, 2H), 6.78–6.66 (m, 2H), 6.63–6.54 (m, 1H), 6.10 (d, *J* = 8.5 Hz, 1H). ¹³C{¹H} NMR (100 MHz, CD₃OD, δ): 138.7, 136.6, 135.7, 135.1, 129.9, 129.5, 128.43, 128.38, 128.1 (q, *J* = 2.0 Hz), 125.9 (q, *J* = 295.0 Hz), 123.2, 120.9, 120.1, 119.8, 118.8, 114.4, 113.3, 112.7, 96.3, 75.7 (q, *J* = 30.0 Hz). ¹⁹F{¹H} NMR (376 MHz, CD₃OD, δ): -73.5. Enantiomeric excess was determined by HPLC (IA column; elute, *n*-hexane/*i*-PrOH = 90/10; detector, 254 nm; flow rate, 1.0 mL/min; 30 °C), retention time 6.7 min (major) and 10.2 min. HRMS (ESI-TOF) (*m*/*z*): [M + H]⁺ calculated for C₂₂H₁₆F₃N₂, 365.1260; found, 365.1258.

(+)-6-Phenyl-6-(trifluoromethyl)-6,11-dihydro-5H-indolo[3,2-c]quinoline (**3ba**'). 4 mg, 5% yield. Pale yellow oil. New compound. R_f = 0.35 (hexanes/ethyl acetate 20:1), 35% ee, $[\alpha]^{20}_D$ = +2.50 (*c* 0.08, EtOAc). ¹H NMR (400 MHz, CD₂Cl₂, δ): 8.48 (brs, 1H), 7.73–7.59 (m, 2H), 7.34–7.21 (m, 5H), 7.07–6.95 (m, 2H), 6.81–6.67 (m, 3H), 6.56 (d, *J* = 8.0 Hz, 1H), 4.56 (brs, 1H). ¹³C{¹H} NMR (100 MHz, CD₂Cl₂, δ): 141.2, 140.3, 137.1, 132.7, 129.3, 128.31, 128.28, 127.9 (q, *J* = 2.0 Hz), 126.7 (q, *J* = 289.0 Hz), 125.8, 122.5, 120.50, 119.6 (q, *J* = 2.0 Hz), 118.3, 113.1, 112.3, 111.1, 104.5, 66.0 (q, *J* = 29.0 Hz). ¹⁹F{¹H} NMR (376 MHz, CD₂Cl₂, δ): -74.9. Enantiomeric excess was determined by HPLC (IB column; elute, *n*-hexane/*i*-PrOH = 90/10; detector, 254 nm; flow rate, 0.8 mL/min; 30 °C), retention time 11.1 min (major) and 12.6 min. HRMS (ESI-TOF) (*m*/z): [M + H]⁺ calculated for C₂₂H₁₆F₃N₂, 365.1260; found, 365.1264.

(+)-12-Ethyl-6-phenyl-6-(trifluoromethyl)-5,6-dihydroindolo[1,2c]quinazoline (3ca). 71 mg, 90% yield. Colorless oil. New compound. $R_{\rm f} = 0.50$ (hexanes/ethyl acetate 20:1), 92% ee, $[\alpha]^{20}_{\rm D} = +38.73$ (c 1.42, EtOAc). ¹H NMR (400 MHz, CD₃OD, δ): 7.71 (dd, J = 7.9, 0.8Hz, 1H), 7.56 (d, J = 7.6 Hz, 2H), 7.41 (d, J = 7.9 Hz, 1H), 7.37-7.26 (m, 3H), 6.99 (d, J = 6.8 Hz, 1H), 6.89–6.69 (m, 3H), 6.64– 6.53 (m, 1H), 6.07 (d, J = 8.5 Hz, 1H), 3.12–2.95 (m, 2H), 1.27 (t, J = 7.5 Hz, 3H). ¹³C{¹H} NMR (100 MHz, CD₃OD, δ): 139.5, 136.9, 134.7, 129.8, 129.4, 129.2, 128.3, 128.2, 127.6, 125.9 (q, J = 295.0 Hz), 124.1, 121.3, 119.5, 118.9, 117.6, 115.9, 114.1, 113.5, 112.6, 75.3 (q, J = 30.0 Hz), 17.8, 13.5. ¹⁹F{¹H} NMR (376 MHz, CD₃OD, δ): -73.0. Enantiomeric excess was determined by HPLC (IA column; elute, *n*-hexane/*i*-PrOH = 95/5; detector, 254 nm; flow rate, 1.0 mL/ min; 30 °C), retention time 5.1 min (major) and 6.5 min. HRMS (ESI-TOF) (m/z): $[M + H]^+$ calculated for $C_{24}H_{20}F_3N_{21}$ 393.1573; found, 393.1592.

(+)-3-Bromo-12-methyl-6-phenyl-6-(trifluoromethyl)-5,6dihydroindolo[1,2-c]quinazoline (**3da**). 26 mg, 28% yield. Colorless oil. New compound. $R_f = 0.70$ (hexanes/ethyl acetate 10:1), 96% ee, $[\alpha]^{20}_{D} = +8.65$ (*c* 0.52, EtOAc). ¹H NMR (400 MHz, CD₃OD, δ): 7.68–7.53 (m, 3H), 7.46–7.31 (m, 4H), 6.96–6.90 (m, 2H), 6.96–6.84 (m, 1H), 6.67–6.58 (m, 1H), 6.07 (d, *J* = 8.5 Hz, 1H), 2.50 (s, 3H). ¹³C{¹H} NMR (100 MHz, CD₃OD, δ): 140.7, 136.4, 134.6, 130.5, 129.6, 128.9, 128.4, 128.1, 125.8 (q, *J* = 295.0 Hz), 125.7, 121.6, 121.5, 120.7, 119.7, 117.9, 115.8, 115.3, 112.5, 107.8, 75.2 (q, *J* = 30.0 Hz), 9.7. ¹⁹F{¹H} NMR (376 MHz, CD₃OD, δ): -73.4. Enantiomeric excess was determined by HPLC (IA column; elute, *n*-hexane/*i*-PrOH = 95/5; detector, 254 nm; flow rate, 1.0 mL/min; 30 °C), retention time 6.1 min (major) and 7.2 min. HRMS (ESI-TOF) (*m*/z): [M + H]⁺ calculated for C₂₃H₁₇BrF₃N₂, 457.0522; found, 457.0532.

(+)-3, 12-Dimethyl-6-phenyl-6-(trifluoromethyl)-5, 6dihydroindolo[1,2-c]quinazoline (**3ea**). 57 mg, 73% yield. Pink solid, mp 190–191 °C. New compound. $R_f = 0.55$ (hexanes/ethyl acetate 20:1), 97% ee, $[\alpha]^{20}_{D} = +39.38$ (*c* 1.14, EtOAc). ¹H NMR (400 MHz, CD₂Cl₂, δ): 7.70 (d, *J* = 8.0 Hz, 1H), 7.59 (d, *J* = 8.0 Hz, 2H), 7.48– 7.30 (m, 4H), 6.95–6.86 (m, 1H), 6.72 (d, *J* = 8.0 Hz, 2H), 7.48– 6.61 (m, 1H), 6.46 (s, 1H), 6.07 (d, *J* = 8.5 Hz, 1H), 4.59 (brs, 1H), 2.55 (s, 3H), 2.21 (s, 3H). ¹³C{¹H} NMR (100 MHz, CD₂Cl₂, δ): 138.3, 138.1, 136.5, 134.6, 130.8, 130.1, 129.8, 128.8, 128.2 (q, *J* = 2.0 Hz), 125.7 (q, *J* = 295.0 Hz), 124.9, 121.7, 121.2, 120.0, 118.2, 114.2, 112.5, 107.6, 75.4 (q, *J* = 30.0 Hz), 21.1, 10.7. ¹⁹F{¹H} NMR (376 MHz, CD₂Cl₂, δ): -72.3. Enantiomeric excess was determined by HPLC (IA column; elute, *n*-hexane/*i*-PrOH = 95/5; detector, 254 nm; flow rate, 1.0 mL/min; 30 °C), retention time 5.6 min (major) and 8.1 min. HRMS (ESI-TOF) (m/z): [M + H]⁺ calculated for C₂₄H₂₀F₃N₂, 393.1573; found, 393.1581.

(+)-10-Bromo-12-methyl-6-phenyl-6-(trifluoromethyl)-5,6dihydroindolo[1,2-c]quinazoline (**3fa**). 70 mg, 77% yield. Colorless oil. New compound. $R_f = 0.55$ (hexanes/ethyl acetate 10:1), 95% ee, $[α]^{20}_D = +66.28$ (c 1.40, EtOAc). ¹H NMR (400 MHz, CD₃OD, δ): 7.73 (dd, J = 7.9, 0.9 Hz, 1H), 7.59–7.51 (m, 3H), 7.39–7.26 (m, 3H), 7.06–6.99 (m, 1H), 6.82–6.72 (m, 2H), 6.67 (dd, J = 8.9, 2.0Hz, 1H), 5.95 (d, J = 8.9 Hz, 1H), 2.45 (s, 3H). ¹³C{¹H} NMR (100 MHz, CD₃OD, δ): 139.6, 136.4, 133.2, 132.5, 131.3, 129.6, 128.4, 128.12, 128.08, 125.9 (q, J = 295.0 Hz), 124.6, 123.8, 120.3, 118.9, 115.7, 114.0, 113.5, 112.9, 106.5, 75.4 (q, J = 30.0 Hz), 9.7. ¹⁹F{¹H} NMR (376 MHz, CD₃OD, δ): -73.2. Enantiomeric excess was determined by HPLC (IA column; elute, *n*-hexane/*i*-PrOH = 95/5; detector, 254 nm; flow rate, 1.0 mL/min; 30 °C), retention time 6.1 min (major) and 7.7 min. HRMS (ESI-TOF) (*m*/*z*): [M + H]⁺ calculated for C₂₃H₁₇BrF₃N₂, 457.0522; found, 457.0546.

(+)-10-Methoxy-12-methyl-6-phenyl-6-(trifluoromethyl)-5,6dihydroindolo[1,2-c]quinazoline (3ga). 69 mg, 84% yield, pink oil. New compound. $R_f = 0.65$ (hexanes/ethyl acetate 10:1), 90% ee, $^{0}_{D}$ = +48.37 (c 0.86, EtOAc). ¹H NMR (400 MHz, CD₃OD, δ): $[\alpha]^{20}$ 7.74 (dd, J = 7.9, 1.0 Hz, 1H), 7.62–7.54 (m, 2H), 7.41–7.29 (m, 3H), 7.02-6.97 (m, 1H) 6.89 (d, J = 2.5 Hz, 1H), 6.82-6.76 (m, 1H), 6.73 (dd, J = 8.0, 0.8 Hz, 1H), 6.26 (dd, J = 9.1, 2.5 Hz, 1H), 5.94 (d, J = 9.1 Hz, 1H), 3.66 (s, 3H), 2.50 (s, 3H). ¹³C{¹H} NMR (100 MHz, CD₃OD, δ): 154.2, 139.4, 136.9, 131.2, 130.5, 129.7, 129.4, 128.3, 128.2, 127.4, 125.9 (q, J = 296.0 Hz), 124.2, 118.7, 116.2, 113.3, 113.2, 111.0, 106.8, 99.6, 75.3 (q, J = 30.0 Hz), 54.7, 9.8. $^{19}\mathrm{F}\{^1\mathrm{H}\}$ NMR (376 MHz, CD₃OD, δ): –73.2. Enantiomeric excess was determined by HPLC (IA column; elute, *n*-hexane/*i*-PrOH = 95/ 5; detector, 254 nm; flow rate, 1.0 mL/min; 30 °C), retention time 7.0 min (major) and 8.2 min. HRMS (ESI-TOF) (m/z): $[M + H]^+$ calculated for C₂₄H₂₀F₃N₂O, 409.1522; found, 409.1530.

(+)-6-(Difluoromethyl)-12-methyl-6-phenyl-5,6-dihydroindolo-[1,2-c]quinazoline (3aj). 72 mg, 99% yield. Colorless oil. New compound. $R_f = 0.55$ (hexanes/ethyl acetate 10:1), 25% ee, $[\alpha]_{D}^{20} =$ +15.94 (c 1.38, EtOAc). ¹H NMR (400 MHz, CD_2Cl_2 , δ): 7.79 (d, J = 7.8 Hz, 1H), 7.65 (d, J = 7.5 Hz, 2H), 7.45 (d, J = 7.9 Hz, 1H), 7.43-7.32 (m, 3H), 7.08-7.00 (m, 1H), 6.94-6.84 (m, 2H), 6.70-6.62 (m, 2H), 6.24 (t, J = 54.5 Hz, 1H), 6.04 (d, J = 8.5 Hz, 1H), 4.63 (brs, 1H), 2.56 (s, 3H). ${}^{13}C{}^{1}H$ NMR (100 MHz, CD_2Cl_2, δ): 138.6, 137.0, 134.9, 130.7, 129.9, 129.3, 128.8, 128.6 (t, J = 2.0 Hz), 128.0, 125.1, 121.9, 120.1, 119.8, 118.4, 117.0, 115.1 (t, J = 254.0 Hz), 114.3, 112.2, 108.3, 74.1 (t, J = 23.0 Hz), 10.8. ¹⁹F{¹H} NMR (376) MHz, CD_2Cl_2 , δ): -123.6 (d, J = 276.8 Hz, 1F), -128.4 (d, J = 276.8 Hz, 1F). Enantiomeric excess was determined by HPLC (IA column; elute, *n*-hexane/*i*-PrOH = 95/5; detector, 254 nm; flow rate, 1.0 mL/ min; 30 °C), retention time 6.7 min (major) and 8.1 min. HRMS (ESI-TOF) (m/z): $[M + H]^+$ calculated for $C_{23}H_{19}F_2N_2$, 361.1511; found. 361.1543.

(+)-6-Benzyl-12-methyl-6-(trifluoromethyl)-5,6-dihydroindolo-[1,2-c]quinazoline (3ak). 70 mg, 89% yield. White solid. mp 145-146 °C. New compound. $R_f = 0.75$ (hexanes/ethyl acetate 10:1), 84% ee, $[\alpha]_{D}^{20}$ = +94.28 (c 1.40, EtOAc). ¹H NMR (400 MHz, CD₂Cl₂, δ): 7.68 (d, J = 7.9 Hz, 1H), 7.59 (d, J = 8.3 Hz, 1H), 7.51 (d, J = 7.8 Hz, 1H), 7.15–6.95 (m, 8H), 6.81 (t, J = 7.6 Hz, 1H), 6.60 (d, J = 7.9 Hz, 1H), 4.32–4.19 (m, 2H), 3.60 (d, J = 15.4 Hz, 1H), 2.48 (s, 3H). ¹³C{¹H} NMR (100 MHz, CD₂Cl₂, δ): 137.6, 134.7, 132.6, 131.1, 130.4, 129.2, 128.4, 128.0, 125.7 (q, J = 295.0 Hz), 127.6, 125.0, 122.6, 120.27, 120.26, 118.9, 116.6, 114.1, 113.2 (q, J = 2.0 Hz), 108.9, 73.8 (q, J = 29.0 Hz), 38.5, 10.9. ¹⁹F{¹H} NMR (376 MHz, CD_2Cl_2 , δ): -78.2. Enantiomeric excess was determined by HPLC (IA column; elute, *n*-hexane/*i*-PrOH = 95/5; detector, 254 nm; flow rate, 1.0 mL/min; 30 °C), retention time 6.3 min (major) and 7.1 min. HRMS (ESI-TOF) (m/z): $[M + H]^+$ calculated for $C_{24}H_{20}F_3N_2$, 393.1573; found, 393.1573.

6,12-Dimethyl-6-phenyl-5,6-dihydroindolo[1,2-c]quinazoline (**3al**). 61 mg, 94% yield. White solid. Known compound.²⁵ $R_f = 0.50$

The Journal of Organic Chemistry

(hexanes/ethyl acetate 10:1), < 1% ee. ¹H NMR (400 MHz, CDCl₃, δ): 7.88 (dd, *J* = 7.9, 1.0 Hz, 1H), 7.66–7.59 (m, 2H), 7.56 (d, *J* = 7.9 Hz, 1H), 7.42–7.34 (m, 3H), 7.14–7.06 (m, 1H), 7.05–6.98 (m, 1H), 6.94 (t, *J* = 7.4 Hz, 1H), 6.85–6.76 (m, 1H), 6.68 (dd, *J* = 7.9, 0.7 Hz, 1H), 6.22 (d, *J* = 8.4 Hz, 1H), 4.24 (brs, 1H), 2.66 (, 3H), 2.02 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃, δ): 143.4, 140.0, 134.1, 130.5, 129.9, 129.0, 128.7, 127.6, 127.5, 125.2, 121.5, 119.8, 119.1, 118.4, 117.9, 115.2, 111.7, 107.3, 73.5, 24.9, 11.1. Enantiomeric excess was determined by HPLC (IB column; elute, *n*-hexane/*i*-PrOH = 70/30; detector, 254 nm; flow rate, 0.7 mL/min; 30 °C), retention time 7.1 and 7.6 min (major).

(+)-*Ethyl* 12-*Methyl*-6-(*trifluoromethyl*)-5,6-*dihydroindolo*[1,2-*c*]*quinazoline*-6-*carboxylate* (**3am**). 56 mg, 75% yield. Pale yellow solid. mp 156–158 °C. New compound. $R_f = 0.40$ (hexanes/ethyl acetate 10:1), 89% ee, $[\alpha]^{20}_{D} = +69.10$ (*c* 1.12, EtOAc). ¹H NMR (400 MHz, CD₃OD, δ): 7.70 (d, *J* = 7.9 Hz, 1H), 7.53–7.43 (m, 1H), 7.10–6.98 (m, 4H), 6.86–6.73 (m, 2H), 4.31–4.14 (m, 2H), 2.49 (s, 3H), 1.07 (t, *J* = 7.1 Hz, 3H). ¹³C{¹H} NMR (100 MHz, CD₃OD, δ): 164.9, 137.8, 134.0, 130.5, 127.8, 124.4, 124.2 (q, *J* = 294.0 Hz), 122.0, 120.2, 119.2, 118.2, 115.5, 113.6, 110.1 (q, *J* = 3.0 Hz), 107.4, 73.7 (q, *J* = 30.0 Hz), 63.1, 12.7, 9.5. ¹⁹F{¹H} NMR (376 MHz, CD₃OD, δ): -77.3. Enantiomeric excess was determined by HPLC (IA column; elute, *n*-hexane/*i*-PrOH = 80/20; detector, 254 nm; flow rate, 0.8 mL/min; 30 °C), retention time 5.4 and 5.9 min (major). HRMS (ESI-TOF) (*m*/z): [M + H]⁺ calculated for C₂₀H₁₈F₃N₂O₂, 375.1315; found, 375.1319.

(+)-*Ethyl* 3,12-*Dimethyl*-6-(*trifluoromethyl*)-5,6-*dihydroindolo*-[1,2-*c*]*quinazoline*-6-*carboxylate* (**3em**). 46 mg, 59% yield. Pink solid. mp 137–138 °C. New compound. $R_f = 0.40$ (hexanes/ethyl acetate 10:1), 91% ee, $[\alpha]^{20}_{D} = +58.80$ (*c* 0.92, EtOAc). ¹H NMR (400 MHz, CD₃OD, δ): 7.58 (d, *J* = 8.5 Hz, 1H), 7.50–7.44 (m, 1H), 7.05–6.98 (m, 3H), 6.67–6.59 (m, 2H), 4.30–4.16 (m, 2H), 2.46 (s, 3H), 2.20 (s, 3H), 1.07 (t, *J* = 7.1 Hz, 3H). ¹³C{¹H} NMR (100 MHz, CD₃OD, δ): 165.0, 138.1, 137.8, 133.9, 130.6, 128.1, 124.4, 124.3 (q, *J* = 294.0 Hz), 121.7, 120.2, 120.1, 118.0, 114.0, 112.9, 110.1 (q, *J* = 2.0 Hz), 106.6, 73.7 (q, *J* = 30.0 Hz), 63.0, 20.1, 12.7, 9.4. ¹⁹F{¹H} NMR (376 MHz, CD₃OD, δ): -77.2. Enantiomeric excess was determined by HPLC (OD-H column; elute, *n*-hexane/*i*-PrOH = 70/30; detector, 254 nm; flow rate, 0.7 mL/min; 30 °C), retention time 5.5 and 5.9 min (major). HRMS (ESI-TOF) (*m*/*z*): [M + H]⁺ calculated for C₂₁H₂₀F₃N₂O₂, 389.1471; found, 389.1475.

(+)-Ethyl 10-Bromo-12-methyl-6-(trifluoromethyl)-5,6dihydroindolo[1,2-c]quinazoline-6-carboxylate (3fm). 47 mg, 52% yield. Pale yellow solid. mp 203–204 °C. New compound. $R_f = 0.45$ (hexanes/ethyl acetate 10:1), 89% ee, $[\alpha]_{D}^{20} = +50.95$ (c 0.94, EtOAc). ¹H NMR (400 MHz, CD_2Cl_2 , δ): 7.75 (d, J = 7.8 Hz, 1H), 7.67 (d, J = 1.9 Hz, 1H), 7.18 (dd, J = 8.8, 1.9 Hz, 1H), 7.15-7.08 (m, 1H), 6.99-6.88 (m, 2H), 6.77 (d, J = 8.0 Hz, 1H), 4.94 (brs, 1H), 4.38-4.19 (m, 2H), 2.50 (s, 3H), 1.14 (t, J = 7.1 Hz, 3H). ¹³C{¹H} NMR (100 MHz, CD₂Cl₂, δ): 164.3, 136.3, 132.8, 132.5, 128.8, 128.7, 125.4, 125.2, 123.7 (q, J = 293 Hz), 121.5, 121.3, 116.0, 114.8, 114.0, 112.3 (q, J = 2.0 Hz), 108.5, 73.9 (q, J = 30.0 Hz), 64.2, 13.6, 10.6. ¹⁹F{¹H} NMR (376 MHz, CD₂Cl₂, δ): -75.8. Enantiomeric excess was determined by HPLC (IA column; elute, *n*-hexane/*i*-PrOH = 70/30; detector, 254 nm; flow rate, 0.7 mL/min; 30 °C), retention time 5.5 min (major) and 6.7 min. HRMS (ESI-TOF) (m/z): $[M + H]^+$ calculated for $C_{20}H_{17}BrF_3N_2O_2$, 453.0420; found, 453.0420.

General Procedure for the Scale-Up Reaction. To a 25 mL sealed tube charged with 2-(1*H*-indolyl)aniline 1a (222 mg, 1.0 mmol), chiral phosphoric acid TRIP (*R*)-4a (37.6 mg, 0.05 mmol), dry toluene (10.0 mL), and 5 Å MS (500 mg), was added ketone 2a (211 μ L, 1.5 mmol) under nitrogen. The mixture was kept stirring at 70 °C for 72 h. The solvent was evaporated under reduced pressure, and the residue was purified by flash column chromatography on a silica gel using hexanes/ethyl acetate (30:1) as the eluent to give the desirable product 3aa (363 mg, 96% yield, 94% ee) as a white solid.

Determination of the Absolute Configuration. The absolute configuration of 12-methyl-6-phenyl-6-(trifluoromethyl)-5,6-dihydroindolo[1,2-c] quinazoline (+)-(**3aa**) was assigned as (R)

based on the X-ray diffraction analysis after recrystallization from a mixture of solvents of methanol/ethyl acetate/hexanes to upgrade ee to >99%. The absolute configurations of the other chiral products are assigned by analogy. The CCDC number is 1873205. These details can be obtained free of charge via www.ccdc.com.ac.uk/data_request/ cif from the Cambridge Crystallographic Data Centre.

Product Elaboration. To a solution of (R)-(+)-**3**am (56 mg, 0.15 mmol, 88% ee) in anhydrous methanol (3 mL), was added sodium borohydride (114 mg, 3.0 mmol) at 0 °C under nitrogen. After being stirred for 30 min, the suspension was warmed to room temperature and stirred overnight. TLC showed **3am** was not consumed completely; sodium borohydride (114 mg, 3.0 mmol) was added in portions until disappearance by TLC. The solvent was evaporated in vacuo, and the residue was dissolved by saturated ammonium solvent and ethyl acetate. The mixture was extracted with ethyl acetate. The combined organic layers were washed with brine and dried over anhydrous sodium sulfate. After being concentrated under the reduced pressure, the residue was purified by flash column chromatography using hexanes/ethyl acetate (4:1) as the eluent to afford the pure product (R)-(-)-**5** (47 mg, 94%) as a white solid.

(-)-(*R*)-(*1*2-*M*ethyl-6-(trifluoromethyl)-5,6-dihydroindolo[1,2-c]quinazolin-6-yl)methanol (**5**). 47 mg, 94% yield. White solid. mp 165–167 °C. New compound. $R_f = 0.30$ (hexanes/ethyl acetate 2:1), 88% ee, $[\alpha]^{20}_{\rm D} = -10.53$ (*c* 0.94, EtOAc). ¹H NMR (400 MHz, CD₃OD, δ): 7.68 (d, *J* = 7.6 Hz, 1H), 7.47 (d, *J* = 7.6 Hz, 2H), 7.11– 6.95 (m, 3H), 6.88–6.74 (m, 2H), 4.67 (d, *J* = 12.2 Hz, 1H), 4.40 (d, *J* = 12.2 Hz, 1H), 2.48 (s, 3H). ¹³C{¹H} NMR (100 MHz, CD₃OD, δ): 139.2, 134.5, 130.8, 129.3, 127.6, 125.6 (q, *J* = 296 Hz), 124.4, 122.1, 119.6, 118.9, 118.0, 116.5, 113.8, 112.2 (q, *J* = 1.0 Hz), 107.3, 74.1 (q, *J* = 28.0 Hz), 61.3, 9.7. ¹⁹F{¹H} NMR (376 MHz, CD₃OD, δ): -78.7. Enantiomeric excess was determined by HPLC (IA column; elute, *n*-hexane/*i*-PrOH = 70/30; detector, 254 nm; flow rate, 0.7 mL/min; 30 °C), retention time 6.2 min (major) and 6.8 min. HRMS (ESI-TOF) (*m*/*z*): [M + H]⁺ calculated for C₁₈H₁₆F₃N₂O, 333.1209; found, 333.1221.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.joc.9b00985.

NMR spectra of products; HPLC for racemic and chiral products of all compounds; and copies of ${}^{1}H$, ${}^{13}C{}^{1}H$, and ${}^{19}F{}^{1}$ spectra of all new compounds (PDF)

X-ray crystallographic data for 3aa (CCDC 1873205) (CIF)

AUTHOR INFORMATION

Corresponding Author

*E-mail: ygzhou@dicp.ac.cn.

ORCID 🔍

Xin-Wei Wang: 0000-0002-0347-2690 Mu-Wang Chen: 0000-0001-6493-1363 Baomin Wang: 0000-0001-9058-4983 Yong-Gui Zhou: 0000-0002-3321-5521

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

Financial support from the National Natural Science Foundation of China (21532006 and 21690074) and Chinese Academy of Sciences (XDB17020300 and QYZDJ-SSW-SLH035) is acknowledged.

The Journal of Organic Chemistry

REFERENCES

(1) (a) Naef, R.; Seebach, D. Preparation of the Enantiomerically Pure cis- and trans-Configurated 2-(tert-Butyl)-3-methylimidazolidin-4-ones from the Amino Acids (S)-Alanine, (S)-Phenylalanine, (R)-Phenylglycine, (S)-Methionine, and (S)-Valine. Helv. Chim. Acta 1985, 68, 135. (b) Ouellet, S. G.; Tuttle, J. B.; MacMillan, D. W. C. Enantioselective Organocatalytic Hydride Reduction. J. Am. Chem. Soc. 2005, 127, 32. (c) Yang, J. W.; Fonseca, M. T. H.; List, B. Catalytic Asymmetric Reductive Michael Cyclization. J. Am. Chem. Soc. 2005, 127, 15036. (d) Militante, J.; Ma, B.-W.; Akk, G.; Steinbach, J. H. Activation and Block of the Adult Muscle-Type Nicotinic Receptor by Physostigmine: Single-Channel Studies. Mol. Pharmacol. 2008, 74, 764. (e) Pérez-Balado, C.; de Lera, A. R. Expedient Total Syntheses of WIN 64745 and WIN 64821. Org. Lett. 2008, 10, 3701. (f) Zuo, Z.; Xie, W.; Ma, D. Total Synthesis and Absolute Stereochemical Assignment of (-)-Communesin F. J. Am. Chem. Soc. 2010, 132, 13226. (g) Zhang, D.; Song, H.; Qin, Y. Total Synthesis of Indoline Alkaloids: A Cyclopropanation Strategy. Acc. Chem. Res. 2011, 44, 447.

(2) (a) Randriambola, L.; Quirion, J.-C.; Kan-Fan, C.; Husson, H.-P. Structure of Goniomitine, A New Type of Indole Alkaloid. *Tetrahedron Lett.* **1987**, *28*, 2123. (b) Lewin, G.; Schaeffer, C.; Hocquemiller, R.; Jacoby, E.; Léonce, S.; Pierré, A.; Atassi, G. Access to New Cytotoxic Bisindole Alkaloids by a Modified Borch Reductive Amination Process. *Heterocycles* **2000**, *53*, 2353. (c) Raoul, M.; Schaeffer, C.; Léonce, S.; Pierré, A.; Atassi, G.; Hocquemiller, R.; Lewin, G. Synthesis of a Novel Series of Cytotoxic Bisindole Alkaloids. *Bioorg. Med. Chem. Lett.* **2001**, *11*, 79.

(3) Cobley, Č. J.; Foucher, E.; Lecouve, J.-P.; Lennon, I. C.; Ramsden, J. A.; Thominot, G. The Synthesis of S 18986, a Chiral AMPA Receptor Modulator, via Catalytic Asymmetric Hydrogenation. *Tetrahedron: Asymmetry* **2003**, *14*, 3431.

(4) (a) Rowland, G. B.; Zhang, H.; Rowland, E. B.; Chennamadhavuni, S.; Wang, Y.; Antilla, J. C. Brønsted Acid-Catalyzed Imine Amidation. J. Am. Chem. Soc. 2005, 127, 15696. (b) Liang, Y.; Rowland, E. B.; Rowland, G. B.; Perman, J. A.; Antilla, J. C. VAPOL Phosphoric Acid Catalysis: The Highly Enantioselective Addition of Imides to Imines. Chem. Commun. 2007, 4477.

(5) For Brønsted acids catalysis, see: (a) Cheng, X.; Vellalath, S.; Goddard, R.; List, B. Direct Catalytic Asymmetric Synthesis of Cyclic Aminals from Aldehydes. J. Am. Chem. Soc. 2008, 130, 15786. (b) Rueping, M.; Antonchick, A. P.; Sugiono, E.; Grenader, K. Asymmetric Brønsted Acid Catalysis: Catalytic Enantioselective Synthesis of Highly Biologically Active Dihydroquinazolinones. Angew. Chem., Int. Ed. 2009, 48, 908. (c) Cheng, D.-J.; Tian, Y.; Tian, S.-K. Catalytic Asymmetric Synthesis of Dihydroquinazolinones from Imines and 2-Aminobenzamides. Adv. Synth. Catal. 2012, 354, 995. (d) Patil, N. T.; Mutyala, A. K.; Konala, A.; Tella, R. B. Tuning the Reactivity of Au-complexes in an Au(I)/Ahiral Brønsted Acid Cooperative Catalytic System: An Approach to Optically Active Fused 1,2-Dihydroisoquinolines. Chem. Commun. 2012, 48, 3094. (e) Huang, D.; Li, X.; Xu, F.; Li, L.; Lin, X. Highly Enantioselective Synthesis of Dihydroquinazolinones Catalyzed by SPINOL-Phosphoric Acids. ACS Catal. 2013, 3, 2244. (f) Zhang, B.; Shi, L.; Guo, R. Enantioselective Synthesis of 2,3-Dihydroquinazolinones Catalyzed by Polymer Supported BINOL-Derived Phosphoric Acid. Catal. Lett. 2015, 145, 1718. (g) Sui, Y.; Cui, P.; Liu, S.; Zhou, Y.; Du, P.; Zhou, H. Highly Enantioselective Synthesis of Cyclic Aminals with a Cyclopentadieneed-Based Chiral Carboxylic Acid. Eur. J. Org. Chem. 2018, 2018, 215.

(6) For metal catalysis, see: (a) Prakash, M.; Kesavan, V. Highly Enantioselective Synthesis of 2,3-Dihydroquinazolinones through Intramolecular Amidation of Imines. *Org. Lett.* **2012**, *14*, 1896. (b) Prakash, M.; Jayakumar, S.; Kesavan, V. Investigation of the Enantioselective Synthesis of 2,3-Dihydroquinazolinones Using Sc-(III)–*Inda*-pybox. *Synthesis* **2013**, *45*, 2265. (c) Deng, T.; Wang, H.; Cai, C. Highly Enantioselective Synthesis of Dihydroquinazolinones through Sc(OTf)₃-Catalyzed Intramolecular Amidation of Imines. *J. Fluorine Chem.* **2015**, *169*, 72. (d) Du, P.; Zhou, H.; Sui, Y.; Liu, Q.; Zou, K. Asymmetric Synthesis of 3,4-Dihydro-2H-1,2,4-benzothiadiazine-1,1-dioxides Catalyzed by Scandium(III)-*Inda*-Pybox. *Tetrahedron* **2016**, *72*, 1573.

(7) For organocatalysis, see: (a) Armstrong, R. J.; D'Ascenzio, M.; Smith, M. D. Cation-Directed Enantioselective N-Functionalization of Pyrroles. Synlett **2015**, 27, 6. (b) Ayyanar, S.; Vijaya, P. K.; Mariyappan, M.; Ashokkumar, V.; Sadhasivam, V.; Balakrishnan, S.; Chinnadurai, C.; Murugesan, S. Enantioselective Synthesis of Dihydroquinazolinone Derivatives Catalyzed by a Chiral Organocatalyst. New J. Chem. **2017**, 41, 7980.

(8) For [3 + 2] cycloadditions, see: (a) Liu, W.-J.; Chen, X.-H.; Gong, L.-Z. Direct Assembly of Aldehydes, Amino Esters, and Anilines into Chiral Imidazolidines via Brønsted Acid Catalyzed Asymmetric 1,3-Dipolar Cycloadditions. Org. Lett. 2008, 10, 5357. (b) Li, Q.-H.; Wei, L.; Chen, X.; Wang, C.-J. Asymmetric Construction of Fluorinated Imidazolidines via Cu(I)-Catalyzed exo'-Selective 1,3-Dipolar Cycloaddition of Azomethine Ylides with Fluorinated Imines. Chem. Commun. 2013, 49, 6277. (c) Zhu, R.-Y.; Wang, C.-S.; Jiang, F.; Shi, F.; Tu, S.-J. Catalytic Asymmetric Homo-1,3-dipolar Cycloadditions of Azomethine Ylides: Diastereo- and Enantioselective Synthesis of Imidazolidines. Tetrahedron: Asymmetry 2014, 25, 617. (d) Ohmatsu, K.; Kawai, S.; Imagawa, N.; Ooi, T. Palladium-Catalyzed Asymmetric [3 + 2] Cycloaddition of 5-Vinyloxazolidinones with Imines Using Chiral Ammonium-Phosphine Hybrid Ligand. ACS Catal. 2014, 4, 4304. (e) Jia, H.; Liu, H.; Guo, Z.; Huang, J.; Guo, H. Tandem [3 + 2] Cycloaddition/1,4-Addition Reaction of Azomethine Ylides and Aza-o-quinone Methides for Asymmetric Synthesis of Imidazolidines. Org. Lett. 2017, 19, 5236. (f) Mukhopadhyay, S.; Pan, S. C. Organocatalytic Asymmetric Synthesis of 2,4-Disubstituted Imidazolidines via Domino Additionaza-Michael Reaction. Chem. Commun. 2018, 54, 964. (g) Yu, B.; Yang, K.-F.; Bai, X.-F.; Cao, J.; Zheng, Z.-J.; Cui, Y.-M.; Xu, Z.; Li, L.; Xu, L.-W. Ligand-Controlled Inversion of Diastereo- and Enantioselectivity in Silver-Catalyzed Azomethine Ylide-Imine Cycloaddition of Glycine Aldimino Esters with Imines. Org. Lett. 2018, 20, 2551.

(9) For [3 + 3] cycloadditions, see: Li, C.; Lu, H.; Sun, X.-X.; Mei, G.-J.; Shi, F. Diastereo- and Enantioselective Construction of Spirooxindole Scaffolds through a Catalytic Asymmetric [3 + 3] Cycloaddition. Org. Biomol. Chem. 2017, 15, 4794.

(10) For [4 + 2] cycloaddition, see: (a) Shao, W.; You, S.-L. Highly Diastereo- and Enantioselective Synthesis of Tetrahydro-5*H*-Indolo-[2,3-*b*]quinolines through Copper-Catalyzed Propargylic Dearomatization of Indoles. *Chem. - Eur. J.* **2017**, *23*, 12489. (b) Wang, C.; Li, Y.; Wu, Y.; Wang, Q.; Shi, W.; Yuan, C.; Zhou, L.; Xiao, Y.; Guo, H. Enantioselective Construction of Tetrahydroquinazoline Motifs via Palladium-Catalyzed [4 + 2] Cycloaddition of Vinyl Benzoxazinones with Sulfamate-Derived Cyclic Imines. *Org. Lett.* **2018**, *20*, 2880.

(11) (a) Zhang, Z.; Antilla, J. C. Enantioselective Construction of Pyrroloindolines Catalyzed by Chiral Phosphoric Acids: Total Synthesis of (-)-Debromoflustramine B. *Angew. Chem., Int. Ed.* **2012**, *51*, 11778. (b) Cai, Q.; Liu, C.; Liang, X.-W.; You, S.-L. Enantioselective Construction of Pyrroloindolines via Chiral Phosphoric Acid Catalyzed Cascade Michael Addition-Cyclization of Tryptamines. *Org. Lett.* **2012**, *14*, 4588. (c) Xie, W.; Jiang, G.; Liu, H.; Hu, J.; Pan, X.; Zhang, H.; Wan, X.; Lai, Y.; Ma, D. Highly Enantioselective Bromocyclization of Tryptamines and Its Application in the Synthesis of (-)-Chimonanthine. *Angew. Chem., Int. Ed.* **2013**, *52*, 12924. (d) Liu, C.; Yi, J.-C.; Liang, X.-W.; Xu, R.-Q.; Dai, L.-X.; You, S.-L. Copper(I)-Catalyzed Asymmetric Dearomatization of Indole Acetamides with 3-Indolylphenyliodonium Salts. *Chem. - Eur. J.* **2016**, *22*, 10813.

(12) He, Y.-P.; Du, Y.-L.; Luo, S.-W.; Gong, L.-Z. Asymmetric Sp^3 C–H Functionalization via a Chiral Brønsted Acid-Catalyzed Redox Reaction for the Synthesis of Cyclic aminals. *Tetrahedron Lett.* **2011**, *52*, 7064.

(13) Li, H.; Belyk, K. M.; Yin, J.; Chen, Q.; Hyde, A.; Ji, Y.; Oliver, S.; Tudge, M. T.; Campeau, L.-C.; Campos, K. R. Enantioselective Synthesis of Hemiaminals via Pd-Catalyzed C-N Coupling with Chiral Bisphosphine Mono-oxides. *J. Am. Chem. Soc.* **2015**, *137*, 13728.

The Journal of Organic Chemistry

(14) (a) Xie, Y.; Zhao, Y.; Qian, B.; Yang, L.; Xia, C.; Huang, H. Enantioselective N–H Functionalization of Indoles with α,β -Unsaturated γ -Lactams Catalyzed by Chiral Brønsted Acids. Angew. Chem., Int. Ed. **2011**, 50, 5682. (b) Trost, B. M.; Gnanamani, E.; Hung, C.-I. Controlling Regioselectivity in the Enantioselective N-Alkylation of Indole Analogues Catalyzed by Dinuclear Zinc-ProPhenol. Angew. Chem., Int. Ed. **2017**, 56, 10451. (c) Cai, Y.; Gu, Q.; You, S.-L. Chemoselective N–H Functionalization of Indole Derivatives via the Reissert-type Reaction Catalyzed by a Chiral Phosphoric Acid. Org. Biomol. Chem. **2018**, 16, 6146. (d) Zhang, L.; Wu, B.; Chen, Z.; Hu, J.; Zeng, X.; Zhong, G. Chiral Phosphoric Acid Catalyzed Enantioselective N-Alkylation of Indoles with *in situ* Generated Cyclic N-Acyl Ketimines. Chem. Commun. **2018**, 54, 9230.

(15) Jiang, Y.; Liu, Y.; Tu, S.-J.; Shi, F. Enantioselective Synthesis of Biologically Important Spiro[indoline-3,2'-quinazolines] via Catalytic Asymmetric Isatin-involved Tandem Reactions. *Tetrahedron: Asymmetry* **2013**, *24*, 1286.

(16) Wang, L.-L.; Jiang, T.; Li, P.-H.; Sun, R.-J.; Zuo, Z. Asymmetric Syntheses of Spirooxindole-dihydroquinazolinones by Cyclization Reactions between N-Substituted Anthranilamides and Isatins. *Adv. Synth. Catal.* **2018**, *360*, 4832.

(17) (a) Shao, Q.; Chen, J.; Tu, M.; Piotrowski, D. W.; Huang, Y. Enantioselective Synthesis of 1,2,4-Triazolines Catalyzed by a Cinchona Alkaloid-derived Organocatalyst. Chem. Commun. 2013, 49, 11098. (b) Jiang, Y.; Pei, C.-K.; Du, D.; Li, X.-G.; He, Y.-N.; Xu, Q.; Shi, M. Enantioselective Synthesis of Spirooxindoles: Asymmetric [3 + 2] Cycloaddition of (3-Isothiocyanato)oxindoles with Azodicarboxylates. Eur. J. Org. Chem. 2013, 2013, 7895. (c) Cui, B.-D.; You, Y.; Zhao, J.-Q.; Zuo, J.; Wu, Z.-J.; Xu, X.-Y.; Zhang, X.-M.; Yuan, W.-C 3-Pyrrolyl-oxindoles as Efficient Nucleophiles for Organocatalytic Asymmetric Synthesis of Structurally Diverse 3,3'-Disubstituted Oxindole Derivatives. Chem. Commun. 2015, 51, 757. (d) Yarlagadda, S.; Ramesh, B.; Reddy, C. R.; Srinivas, L.; Sridhar, B.; Reddy, B. V. S. Organocatalytic Enantioselective Amination of 2-Substituted Indolin-3-ones: A Strategy for the Synthesis of Chiral α -Hydrazino Esters. Org. Lett. 2017, 19, 170. (e) Ñíguez, D. R.; Khazaeli, P.; Alonso, D. A.; Guillena, G. Deep Eutectic Mixtures as Reaction Media for the Enantioselective Organocatalyzed α -Amination of 1,3-Dicarbonyl Compounds. Catalysts 2018, 8, 217.

(18) (a) Müller, K.; Faeh, C.; Diederich, F. Fluorine in Pharmaceuticals: Looking Beyond Intuition. *Science* 2007, 317, 1881. (b) Hagmann, W. K. The Many Roles for Fluorine in Medicinal Chemistry. J. Med. Chem. 2008, 51, 4359. (c) Ma, J.-A.; Cahard, D. Asymmetric Fluorination, Trifluoromethylation, and Perfluoroalkylation Reactions. Chem. Rev. 2008, 108, PR1. (d) Purser, S.; Moore, P. R.; Swallow, S.; Gouverneur, V. Fluorine in Medicinal Chemistry. Chem. Soc. Rev. 2008, 37, 320. (e) Petrov, V. A. Fluorinated Heterocyclic Compounds: Synthesis, Chemistry, and Applications; Wiley: Hoboken, NJ, 2009. (f) Nie, J.; Guo, H.-C.; Cahard, D.; Ma, J.-A. Asymmetric Construction of Stereogenic Carbon Centers Featuring a Trifluoromethyl Group from Prochiral Trifluoromethylated Substrates. Chem. Rev. 2011, 111, 455. (g) Liu, Y.-L.; Shi, T.-D.; Zhou, F.; Zhao, X.-L.; Wang, X.; Zhou, J. Org. Lett. 2011, 13, 3826.

(19) Hiramatsu, K.; Honjo, T.; Rauniyar, V.; Toste, F. D. Enantioselective Synthesis of Fluoro-Dihydroquinazolones and -Benzooxazinones by Fluorination-Initiated Asymmetric Cyclization Reactions. *ACS Catal.* **2016**, *6*, 151.

(20) For fluorine effect in organocatalysis, see: (a) Liu, Y.-L.; Shi, T.-D.; Zhou, F.; Zhao, X.-L.; Wang, X.; Zhou, J. Organocatalytic Asymmetric Strecker Reaction of Di- and Trifluoromethyl Ketoimines. Remarkable Fluorine Effect. *Org. Lett.* **2011**, *13*, 3826. (b) Volla, C. M. R.; Das, A.; Atodiresei, I.; Rueping, M. Fluorine effects in organocatalysis – asymmetric Brønsted acid assisted Lewis base catalysis for the synthesis of trifluoromethylated heterocycles exploiting the negative hyperconjugation of the CF₃-group. *Chem. Commun.* **2014**, *50*, 7889. (c) Lou, H.; Wang, Y.; Jin, E.; Lin, X. Organocatalytic Asymmetric Synthesis of Dihydrobenzo Bearing Trifluoromethylated Quaternary Stereocenters. J. Org. Chem. 2016, 81, 2019.

(21) (a) Kohn, H.; Sawhney, K. N.; LeGall, P.; Robertson, D. W.; Leander, J. D. Preparation and Anticonvulsant Activity of a Series of Functionalized α -Heteroatom-Substituted Amino Acids. J. Med. Chem. **1991**, 34, 2444. (b) Choi, D.; Stables, J. P.; Kohn, H. Synthesis and Anticonvulsant Activities of N-Benzyl-2-acetamidopropionamide Derivatives. J. Med. Chem. **1996**, 39, 1907. (c) Yaouancq, L.; René, L.; Dau, M.-E. T. H.; Badet, B. Toward Synthesis of α -Alkyl Amino Glycines (A3G), New Amino Acid Surrogates. J. Org. Chem. **2002**, 67, 5408. (d) Shen, M.; LeTiran, A.; Xiao, Y.; Golbraikh, A.; Kohn, H.; Tropsha, A. Quantitative Structure-Activity Relationship Analysis of Functionalized Amino Acid Anticonvulsant Agents Using k Nearest Neighbor and Simulated Annealing PLS Methods. J. Med. Chem. **2002**, 45, 2811.

(22) (a) Copey, L.; Jean-Gérard, L.; Framery, E.; Pilet, G.; Andrioletti, B. Synthesis, Solid-State Analyses, and Anion-Binding Properties of *meso*-Aryldipyrrin-5,5-diylbis(phenol) and -bis(aniline) Ligands. *Eur. J. Org. Chem.* 2014, 2014, 4759. (b) Rubio-Presa, R.; Pedrosa, M. R.; Fernández-Rodríguez, M. A.; Arnáiz, F. J.; Sanz, R. Molybdenum-Catalyzed Synthesis of Nitrogenated Polyheterocycles from Nitroarenes and Glycols with Reuse of Waste Reduction Byproduct. *Org. Lett.* 2017, 19, 5470.

(23) Gauthier, D.; Dodd, R. H.; Dauban, P. Regioselective Access to Substituted Oxindoles via Rhodiumcatalyzed Carbene C–H Insertion. *Tetrahedron* **2009**, *65*, 8542.

(24) Billimoria, A. D.; Cava, M. P. Chemistry of Indolo[1,2c]quinazoline: An Approach to the Marine Alkaloid Hinckdentine A. J. Org. Chem. **1994**, 59, 6777.

(25) Lakshmi, P. G. V. V.; Patil, N. T. An Efficient Synthesis of Indolo[1,2-c]quinazolines. Asian J. Chem. 2014, 26, 2893.